Vemurafenib: the first drug approved for BRAF-mutant cancer

  title={Vemurafenib: the first drug approved for BRAF-mutant cancer},
  author={Gideon E. Bollag and James Tsai and Jiazhong Zhang and Chao Michael Zhang and Prabha N. Ibrahim and Keith Nolop and Peter Hirth},
  journal={Nature Reviews Drug Discovery},
The identification of driver oncogenes has provided important targets for drugs that can change the landscape of cancer therapies. One such example is the BRAF oncogene, which is found in about half of all melanomas as well as several other cancers. As a druggable kinase, oncogenic BRAF has become a crucial target of small-molecule drug discovery efforts. Following a rapid clinical development path, vemurafenib (Zelboraf; Plexxikon/Roche) was approved for the treatment of BRAF-mutated… CONTINUE READING
Highly Influential
This paper has highly influenced 10 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 98 times over the past 90 days. VIEW TWEETS

From This Paper

Figures, tables, and topics from this paper.


Publications citing this paper.
Showing 1-10 of 183 extracted citations


Publications referenced by this paper.
Showing 1-10 of 146 references

A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib

  • O Gautschi
  • J. Thorac. Oncol. 7,
  • 2012

Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer

  • H Yang
  • Cancer Res
  • 2012

Similar Papers

Loading similar papers…